

ABOUT THE TEST FoundationOne®Liquid is a next generation sequencing (NGS) assay that identifies clinically relevant genomic alterations in circulating tumor DNA.

PATIENT

DISEASE Lung adenocarcinoma
 NAME Not Given
 DATE OF BIRTH Not Given
 SEX Not Given
 MEDICAL RECORD # Not Given

PHYSICIAN

ORDERING PHYSICIAN Not Given
 MEDICAL FACILITY Not Given
 ADDITIONAL RECIPIENT Not Given
 MEDICAL FACILITY ID Not Given
 PATHOLOGIST Not Given

SPECIMEN

SPECIMEN ID Not Given
 SPECIMEN TYPE Blood
 DATE OF COLLECTION Not Given
 SPECIMEN RECEIVED Not Given

Biomarker Findings
 MSI Status Undetermined

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

EGFR exon 19 deletion (L747_A750>P)
TP53 C242G

7 Therapies with Clinical Benefit
0 Therapies with Lack of Response

10 Clinical Trials

BIOMARKER FINDINGS
ACTIONABILITY
MSI Status Undetermined

GENOMIC FINDINGS	MAF %	THERAPIES WITH CLINICAL BENEFIT (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL BENEFIT (IN OTHER TUMOR TYPE)
EGFR - exon 19 deletion (L747_A750>P)	0.20%	Afatinib Erlotinib Gefitinib Osimertinib	Cetuximab Lapatinib Panitumumab
10 Trials see p. 8			

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIALS OPTIONS


For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

TP53 - C242G p. 3

NOTE Genomic alterations detected may be associated with activity of certain FDA-approved drugs; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. In the appropriate clinical context, germline testing of APC, BRCA1, BRCA2, CDH1, NF1, PALB2, RBT, RET, STK11, and TP53 is recommended.

Mutant Allele Frequency is not applicable for copy number amplifications or rearrangements.

CRF# XXXXXXXX



HISTORIC PATIENT FINDINGS	TEST 1	TEST 2 MAF%	TEST 3 MAF%	CHANGE FROM PREV.
Tumor Mutational Burden	Cannot Be Determined	Not Tested	Not Tested	—
Microsatellite status	Cannot Be Determined	n/a	n/a	—
EGFR ● exon 19 deletion (L747_A750>P)	detected	23.00%	0.20%	-22.8%
TP53 ● C242G	detected	12.50%	0.10%	-12.40%

NOTE This comparison table refers only to genes and biomarkers assayed by prior FoundationOne®Liquid or FoundationOne® tests. Up to five previous tests may be shown.

For some genes in FoundationOne Liquid only select exons are assayed. Therefore, an alteration found by a previous test may not have been confirmed despite overlapping gene lists. Please refer to the Appendix for the complete list of genes and exons assayed. The gene and biomarker list will be updated periodically to reflect new knowledge about cancer biology.

As new scientific information becomes available, alterations that had previously been listed as Variants of Unknown Significance (VUS) may become reportable.